<?xml version="1.0" encoding="UTF-8"?>
<p id="par0020">Influenza represents an annual global health problem, with such an impact that the CDC estimates between 23,000 and 61,000 deaths per year from 2015 to 2019 in the US alone [
 <xref rid="bib0005" ref-type="bibr">1</xref>]. The spectrum of disease varies and can range from a febrile upper respiratory disease to Acute Respiratory Distress Syndrome (ARDS), the latter often requiring mechanical ventilation. Current guidelines recommend that patients requiring hospitalization for influenza-related illness should receive oseltamivir, regardless the time of symptoms onset. Duration of treatment should be decided on a case-by-case basis [
 <xref rid="bib0010" ref-type="bibr">2</xref>]. The recommendations are based on the available evidence that neuraminidase inhibitors (NAI) have been shown to decrease mortality, length of stay and complications. However, a new family of influenza drugs has been approved for use, namely endonuclease inhibitors (EI), represented by baloxavir marboxil.
</p>
